Epigenomics
Manufacturing · Germany · 11-50 Employees
View Company Info for Free
Overview
Headquarters
Geneststraße 5, Berlin, Berlin, 10829, G...Phone Number
(800) 343-9921Website
www.epigenomics.comRevenue
$6.6 MillionStock Symbol
EPGNYIndustry
ZI Rank: 1
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
2
1
1
1
1
1
About Epigenomics
Epigenomics is a molecular diagnostics company focused on blood-based detection of cancers using its proprietary DNA methylation biomarker technology. The company develops and commercializes diagnostic products across multiple cancer indications with high medical need. Epigenomics' lead product, Epi proColon, is a blood-based screening test for the detection of colorectal cancer. Epi proColon has received approval from the U.S. Food and Drug Administration (FDA) and is currently marketed in the United States, Europe, China and selected other countries. Epigenomics' second product, Epi proLung(R), is in development as a blood-based test for lung cancer detection.Explore more
Epigenomics Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Epigenomics your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Website visits: Recent activity has been detected on your website
Click to see if Epigenomics had a recent Job posting/layoffs
Check out if Epigenomics is spiking on competitors!
Product Launch: Get notified when Epigenomics launches new products
Check if Epigenomics has recently received funding, and reach out quickly before it becomes old news!
Epigenomics, which may be a good buyer, showed buying intent in Masked Content Topic
Earning: See what the market has to say on Epigenomics recently announced quarterly report
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Congratulate Masked Content for being promoted to Masked Content at Epigenomics
Funding: Get notified immidiatlly once Epigenomics has new funding data
Recommended Actions
Find VP level buyers at Epigenomics
Find more new buyers
Company Profile Activity
Activity Insights
Epigenomics is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Epigenomics is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Epigenomics.
Epigenomics financials insights
Gather financial insights about Epigenomics, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2004
Stock Offering
$51.5M
2014
Share Placement
$5.3M
2016
Multiple Rounds
$15.2M
2017
Debt
$7M
Share Placement
$6M
2018
Share Placement
$24.3M
2019
Share Placement
$8.2M
2020
Share Placement
$4.4M
Epigenomics Tech Stack
A closer look at the technologies used by Epigenomics
See more technologies
Most Recent Scoops
Earnings
Epigenomics has recently released 2024 H1 report with the following insight: The main goals were to secure financing for Epi proColon "Next Gen" pivotal trial and commercialization. With failure to find financing, the goals shifted to major restructuring to reduce costs and preserve cash while seeking buyers for key assets. The focus is now on completing an asset sale to New Day Diagnostics and shareholder approval.
Asset Management, Business Intelligence, Information Security, Financial Planning, Sales, Demand Generation, Sales Development, Security
Earnings
Consolidation, Asset Management
Mergers & Acquisitions (M&A)
Left Company
Executive Move
Board of Directors
Left Company
Executive Move
Board of Directors
Epigenomics News & Media
New Day Diagnostics Announces Approval of Purchase Agreement by Epigenomics' AG Extraordinary General Meeting
KNOXVILLE, Tenn.--(BUSINESS WIRE)--New Day Diagnostics is pleased to announce that the Extraordinary General Meeting of Epigenomics AG (Frankfurt General Standard: ECX1), a molecular diagnostics company focused on blood testing for the early detection of cancer, has approved the acquisition agreement between the two organizations. The agreement's completion will further enhance New Day Diagnostics' ability to improve lives by empowering people with innovative, accessible diagnostics. “New Day DNew Day Diagnostics LLC Reinforces Commitment to Early Cancer Intervention with Its intention to Acquire the Assets of Epigenomics AG
KNOXVILLE, Tenn.--(BUSINESS WIRE)--New Day Diagnostics LLC is pleased to announce that it has entered into an asset purchase agreement with Epigenomics AG (Frankfurt Prime Standard: ECX, OTCQX: EPGNY), a molecular diagnostics company focused on blood testing for the early detection of cancer. This agreement is the successful result of negotiations previously disclosed by Epigenomics AG in their ad hoc announcement dated June 12, 2023. Today's announcement comes on the heels of New Day DiagnostiEstimating The Intrinsic Value Of Epigenomics AG (ETR:ECX1)
Key Insights Using the 2 Stage Free Cash Flow to Equity, Epigenomics fair value estimate is €0.99 With €0.88 share...Epigenomics AG: Chief Executive Officer Greg Hamilton Resigns | MarketScreener
EQS-News: Epigenomics AG / Key word: Personnel Epigenomics AG: Chief Executive Officer Greg Hamilton Resigns 12.04.2023 / 20:05 CET/CEST The issuer is solely responsible for the... | April 12, 2023
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Frequently Asked Questions Regarding Epigenomics
Sign Up For FreeTo access detailed company insights
Epigenomics is a molecular diagnostics company focused on blood-based detection of cancers using its proprietary DNA methylation biomarker technology. The company develops and commercializes diagnostic products across multiple cancer indications with high medical need. Epigenomics' lead product, Epi proColon, is a blood-based screening test for the... Read More
